Visual Outcomes in Leber Hereditary Optic Neuropathy Patients With the m.11778G>A (MTND4) Mitochondrial DNA Mutation
The DOI matches its Crossref record; 50 of the 53 references it cites were found in a registry or an index.
Abstract
BACKGROUND Leber hereditary optic neuropathy (LHON) is a maternally inherited bilaterally blinding optic neuropathy, predominantly affecting otherwise healthy young individuals, mostly men. The visual prognosis is generally poor, with most patients worsening to at least 20/200 visual acuity. The m.11778G>A (MTND4) mitochondrial DNA mutation is the most common cause of LHON and is associated with poor outcomes and limited potential for meaningful visual recovery. Treatments for LHON are limited, and clinical trials are hampered by inadequate data regarding the natural history of visual loss and recovery. In this article, we review the current literature specifically related to visual function of LHON patients with the m.11778G>A mutation. EVIDENCE ACQUISITION Literature review was performed using MEDLINE through PubMed, Cochrane Reviews Library, and Orpha.net with search terms of "Leber hereditary optic neuropathy," "LHON," "ND4," "G11778A," "visual acuity," "nadir," "natural history," and "registry." All English-language, peer-reviewed publications with study cohorts of at least 5 LHON patients with the molecularly confirmed m.11778G>A mutation were included. RESULTS Meta-analysis of 12 retrospective and 3 prospective studies provided visual function information on 695 LHON patients with the m.11778G>A mutation, 100 (14.4%) of whom were reported to have "recovered" some vision, although definitions of "recovery" varied among studies and idebenone use could not always be exclu…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Spontaneous recovery occurs in a minority of patients (14.4% in a recent large meta-analysis), 5 and most patients remain severely visually impaired. 6”
From Efficacy and Safety of Intravitreal Gene Therapy for Leber Hereditary Optic Neuropathy Treated within 6 Months of Disease Onset (2021) · cites this paper as [5]
In the citing paper
“Unfortunately, adequate prospective natural history studies with sufficient sample sizes of LHON patients stratified by mutation and age, and followed regularly with standardized measures of visual function at consistent intervals from the time of onset of visual loss until 96 weeks or longer are lacking, making direct comparison to our study challenging.”
From Efficacy and Safety of Intravitreal Gene Therapy for Leber Hereditary Optic Neuropathy Treated within 6 Months of Disease Onset (2021) · cites this paper as [5]
In the citing paper
“In a recent meta-analysis of English-language peer-reviewed publications with study cohorts of at least 5 LHON patients confirmed to carry the m.11778G>A mutation, 12 retrospective and 3 prospective studies were identified providing visual function information on 695 subjects, among whom 100 (14.4%) were reported to have recovered some vision, although definitions of recovery varied among studies.”
From Efficacy and Safety of Intravitreal Gene Therapy for Leber Hereditary Optic Neuropathy Treated within 6 Months of Disease Onset (2021) · cites this paper as [5]
In the citing paper
“However, this cohort included an unspecified percentage of subjects with childhood-onset LHON, for whom spontaneous visual recovery, even years after onset, is more frequent than among patients with adult onset.5”
From Efficacy and Safety of Intravitreal Gene Therapy for Leber Hereditary Optic Neuropathy Treated within 6 Months of Disease Onset (2021) · cites this paper as [5]
In the citing paper
“Specifically focusing on those patients who were at least 15 years old at the time of visual loss, spontaneous meaningful visual recovery occurred in 23 of 204 (11.3%) cases.”
From Efficacy and Safety of Intravitreal Gene Therapy for Leber Hereditary Optic Neuropathy Treated within 6 Months of Disease Onset (2021) · cites this paper as [5]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Mitochondrial DNA mutation associated with Leber’s hereditary optic neuropathy
Wallace, D. C., Singh, G., Lott, M. T., Hodge, J. A., Schurr, T. G., Lezza, A. M. S., Elsas, L. J., & Nikoskelainen, E. K. (1988) · Science · doi:10.1126/science.3201231 · Cited by 2,440 · cited 3×
“DNA (mtDNA) (1), affecting approximately 1 in 30,000 to 1 in 50,000 people, particularly young adult males (2).”
BackgroundA randomized placebo-controlled trial of idebenone in Leber’s hereditary optic neuropathy.
Klopstock, T., Yu-Wai-Man, P., Dimitriadis, K., Rouleau, J., Heck, S., Bailie, M., Atawan, A., Chattopadhyay, S., Schubert, M., Garip, A., et al. (2011) · Brain · doi:10.1093/brain/awr170 · Cited by 578 · cited 7×
“(27) 18 (placebo arm) Duration of vision loss (mean): 24.”
BackgroundInfluentialSelf-citationRiordan-Eva, P., Sanders, M. D., Govan, G. G., Sweeney, M. G., Costa, J. D., & Harding, A. E. (1995) · Brain · doi:10.1093/brain/118.2.319 · Cited by 490
The Epidemiology of Leber Hereditary Optic Neuropathy in the North East of England
Man, P. Y. W., Griffiths, P. G., Brown, D. T., Howell, N., Turnbull, D. M., & Chinnery, P. F. (2003) · The American Journal of Human Genetics · doi:10.1086/346066 · Cited by 483 · cited 1×
“DNA (mtDNA) (1), affecting approximately 1 in 30,000 to 1 in 50,000 people, particularly young adult males (2).”
BackgroundSelf-citationNewman, N. J., Lott, M. T., & Wallace, D. C. (1991) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(14)76784-4 · Cited by 403 · cited 8×
“Retrospective Newman et al (5) 56 50 Final outcome VA better than 20/200 0% (0/50) 0% (0/98)*”
BackgroundInfluentialSelf-citationLeber's Hereditary Optic Neuropathy: Clinical Manifestations of the 3460 Mutation
Johns, D. R. (1992) · Archives of Ophthalmology · doi:10.1001/archopht.1992.01080230077025 · Cited by 247
BARBONI, P., SAVINI, G., VALENTINO, M., MONTAGNA, P., CORTELLI, P., DENEGRI, A., SADUN, F., BIANCHI, S., LONGANESI, L., & ZANINI, M. (2005) · Ophthalmology · doi:10.1016/j.ophtha.2004.06.034 · Cited by 247
Idebenone Treatment In Leber's Hereditary Optic Neuropathy
Carelli, V., La Morgia, C., Valentino, M. L., Rizzo, G., Carbonelli, M., De Negri, A. M., Sadun, F., Carta, A., Guerriero, S., Simonelli, F., et al. (2011) · Brain · doi:10.1093/brain/awr180 · Cited by 241 · cited 6×
“Meta-analysis of LHON subjects with the m.11778G.A mutation and age $15 years old at onset Study Total Number of Subjects Subjects $15 Years Old Recovery Criteria for Recovery Patients (n/N)—in at Least 1 Eye Eyes (n/N) Retrospective Newman et al (5) 56 50 Final outcome VA better than 20/200 0% (0/50) 0% (0/98)* Riord…”
BackgroundInfluentialSelf-citationCarelli, V., Carbonelli, M., de Coo, I. F., Kawasaki, A., Klopstock, T., Lagrèze, W. A., La Morgia, C., Newman, N. J., Orssaud, C., Pott, J. W. R., et al. (2017) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0000000000000570 · Cited by 228 · cited 3×
“Subjects typically experience a subacute painless loss of central vision, either simultaneously recognized in both eyes (25%–50% of the time), or in one eye followed by sequential impairment of he second eye with days, weeks or months (50%–75% of the time), with at least 97% of patients having bilateral involvement wi…”
BackgroundInfluentialSelf-citationBarboni, P., Carbonelli, M., Savini, G., Ramos, C. D. V. F., Carta, A., Berezovsky, A., Salomao, S. R., Carelli, V., & Sadun, A. A. (2010) · Ophthalmology · doi:10.1016/j.ophtha.2009.07.026 · Cited by 215
Self-citation
Cited by
Yu-Wai-Man, P., Newman, N. J., Carelli, V., Moster, M. L., Biousse, V., Sadun, A. A., Klopstock, T., Vignal-Clermont, C., Sergott, R. C., Rudolph, G., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz7423 · Cited by 232
Self-citationClemente-Suárez, V., Redondo-Flórez, L., Beltrán-Velasco, A., Ramos-Campo, D., Belinchón-deMiguel, P., Martinez-Guardado, I., Dalamitros, A., Yáñez-Sepúlveda, R., Martín-Rodríguez, A., & Tornero-Aguilera, J. (2023) · Biomedicines · doi:10.3390/biomedicines11092488 · Cited by 219
Newman, N. J., Yu-Wai-Man, P., Carelli, V., Moster, M. L., Biousse, V., Vignal-Clermont, C., Sergott, R. C., Klopstock, T., Sadun, A. A., Barboni, P., et al. (2021) · Ophthalmology · doi:10.1016/j.ophtha.2020.12.012 · Cited by 168
“However, this cohort included an unspecified percentage of subjects with childhood-onset LHON, for whom spontaneous visual recovery, even years after onset, is more frequent than among patients with adult onset.(5) Guy et al,(35,36) at the University of Miami, have also developed a self-complementary adeno-associated…”
BackgroundResultSelf-citationRetinal Ganglion Cells—Diversity of Cell Types and Clinical Relevance
Kim, U. S., Mahroo, O. A., Mollon, J. D., & Yu‐Wai‐Man, P. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.661938 · Cited by 202
“11778G>A mutation experiencing some visual recovery (159, 163).”
BackgroundSelf-citationNewman, N. J., Yu-Wai-Man, P., Biousse, V., & Carelli, V. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00174-0 · Cited by 97
Self-citation
Metadata
- Authors
- Newman, N. J., Carelli, V., Taiel, M., & Yu-Wai-Man, P.
- Affiliations
- Emory University (US)
- Corresponding author
- Newman, Nancy J.
- Venue
- Journal of Neuro-Ophthalmology
- Published
- 2020-09-21
- Volume
- 40
- Issue
- 4
- Pages
- 547-557
- ISSN
- 1070-8022 (ISSN-L)
- OpenAlex
- W3088837836
- Cited by
- 111
- References
- 53
- Citations by year
- 2026: 11 · 2025: 16 · 2024: 20 · 2023: 20 · 2022: 23 · 2021: 16 · 2020: 4
- FWCI
- 1.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Neuro-Ophthalmology (publishedVersion)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Funders
- Sight Research UK (SEE 003)
- National Eye Institute (P30EY006360)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
- Health Sciences › Medicine › Ophthalmology › Glaucoma and retinal disorders
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Hereditary Neurological Disorders
- Keywords
- Leber's hereditary optic neuropathy, m.11778G>A mutation, mitochondrial DNA mutations, visual prognosis, visual acuity, visual recovery, age of onset, idebenone, optic neuropathy, pediatric patients, visual function outcomes
- MeSH terms
- DNA Mutational Analysis, DNA, Mitochondrial, Humans, NADH Dehydrogenase, Visual Acuity, Point Mutation, Optic Atrophy, Hereditary, Leber
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Visual Outcomes in Leber Hereditary Optic Neuropathy Patients With the m.11778G>A (MTND4) Mitochondrial DNA Mutation. https://app.cochat.ai/papers/10.1097/wno.0000000000001045
- The paper
- Newman, N. J., Carelli, V., Taiel, M., & Yu-Wai-Man, P. (2020). Visual Outcomes in Leber Hereditary Optic Neuropathy Patients With the m.11778G>A (MTND4) Mitochondrial DNA Mutation. Journal of Neuro-Ophthalmology. https://doi.org/10.1097/wno.0000000000001045
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.